--News Direct--

AdAlta Ltd (ASX:1AD) CEO Dr Tim Oldham tells Proactive the company has wrapped up the enrolment of healthy volunteers for its AD-214 Phase 1 extension study, and early indications are that it is well tolerated. The aim of the trial is to evaluate the safety of AD-214, the company’s flagship candidate for treating fibrotic diseases including Idiopathic Pulmonary Fibrosis.

Oldham said: “We are grateful to all the volunteers that have participated in this Phase 1 extension study.

“The data being generated continues to show that AD-214 is well tolerated and is also helping to inform dosing regimens and the broader protocol for our coming Phase 2 study for AD-214.”

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/adalta-completes-enrolment-for-ad-214-fibrosis-safety-trial-650972057